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Methods: We performed genome-wide linkage and identity-by-descent (IBD) analyses on 41
non-Hispanic white families exhibiting likely dominant inheritance of LOAD, and having no
mutations at known familial Alzheimer’s disease (AD) loci, and a low burden of APOE ε4 al-
leles.
Results: Two-point parametric linkage analysis identified 14 significantly linked regions, including
three novel linkage regions for LOAD (5q32, 11q12.2–11q14.1, and 14q13.3), one of which repli-
cates a genome-wide association LOAD locus, the MS4A6A-MS4A4E gene cluster at 11q12.2.
Five of the 14 regions (3q25.31, 4q34.1, 8q22.3, 11q12.2–14.1, and 19q13.41) are supported by
strong multipoint results (logarithm of odds [LOD*] 1.5). Nonparametric multipoint analyses pro-
duced an additional significant locus at 14q32.2 (LOD* 5 4.18). The 1-LOD confidence interval
for this region contains one gene, C14orf177, and the microRNA Mir_320, whereas IBD analysesrs has a conflict of interest.
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B.W. Kunkle et al. / Alzheimer’s & Dementia 12 (2016) 2-10 3implicates an additional gene BCL11B, a regulator of brain-derived neurotrophic signaling, a
pathway associated with pathogenesis of several neurodegenerative diseases.
Discussion: Examination of these regions after whole-genome sequencing may identify highly pene-
trant variants for familial LOAD.
 2016 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
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Althoughmore than two dozen loci that contribute to late-
onset Alzheimer disease (LOAD) have been identified [1],
few genes with highly penetrant rare variants (e.g., APP,
PSEN1, and PSEN2 in early-onset familial Alzheimer’s dis-
ease [AD] [2]) that explain risk in families heavily burdened
with LOAD have been found. It is likely that rare variants
contribute to complex disease, however [3], and recent re-
ports implicating rare variants in PLD3, APP, and TREM2
[4–7] support their involvement in both sporadic and
familial LOAD. Identification of additional rare mutations
driving genetic risk in familial LOAD will help in defining
new pathways for therapeutic and preventive treatments.
Linkage analysis in large multiplex pedigrees is a robust
approach for identifying disease loci in the presence of
allelic heterogeneity, and thus can be valuable for targeting
regions for sequencing studies [8]. To identify genomic re-
gions likely to contain rare (minor allele frequency [MAF]
0.01) and low-frequency (0.01  MAF  0.05) LOAD
risk and possibly protective genetic variants, a large number
of well-characterized families were screened for inclusion in
a linkage scan. The selected extended families are uniquely
suited for discovery of genomic regions containing high
penetrant AD variants. We performed extensive parametric
two-point and nonparametric multipoint linkage analysis
on 385 individuals in 41 non-Hispanic white (NHW) fam-
ilies. Loci identified through this study can help prioritize
regions of the genome for analyses of whole-exome or
whole-genome sequence data from NHW LOAD families
or case-control cohorts.2. Methods
2.1. Study samples
The 42 NHW families selected for linkage analyses are
from five collections assembled by investigators at the Uni-
versity of Pennsylvania (eight families), the University of
Miami (12 families), Case Western University (one family),
the National Institute on Aging Late-Onset Alzheimer’s
Disease (NIALOAD) family study (17 families), and the
National Cell Repository for Alzheimer’s Disease (four
families). Detailed descriptions of the ascertainment and
evaluation of subjects in these cohorts have been providedelsewhere [9–11]. To maximize the probability of detecting
segregating novel rare variants, we developed several
selection criteria including (1) having four or more affected
individuals with genomic DNA samples; (2) exhibiting
likely dominant inheritance of LOAD; (3) free of known
mutations at established Alzheimer’s Disease/
Frontotemporal Dementia Mendelian loci (APP, PSEN1,
PSEN2, MAPT, or GRN); and (4) reduced representation of
the APOE ε4 allele. Criterion number 4 included prioritized
selection of families with APOE ε2/ε2, ε2/ε3, and ε3/ε3
affected individuals (requiring at least one affected family
member without any APOE ε4 allele and any affected
individuals with a single APOE ε4 must have age at onset
[AAO] ,72). In the 41 NHW families ultimately analyzed,
385 individuals (3–11 cases per pedigree) had genotyping
data available and were included in the present analyses. Of
those families, 75.6% (31 of 41) have at least one autopsy
confirmed LOAD case (Table 1).2.2. Genotyping and quality control procedures
Genome-wide single-nucleotide polymorphism (SNP)
genotyping was performed on several different platforms
across the study cohorts, including the Illumina Human-
Hap550, Illumina 1M, HumanOmniExpress, HumanOm-
niExpress Exome, and HumanOmni2.5 arrays. A call rate
threshold of 98% was applied, and the data were then
merged to form a final linkage data set for analysis. SNPs
were only included in the analysis if they were present in
at least 60% of samples; 319,409 SNPs were selected for
analysis and aligned to the Rutgers Map v.3 [12]. Among
this group of SNPs, 26,959 were excluded because the
MAF was less than 0.05 and/or the genotype distribution
differed significantly (P , 1026 in controls) from Hardy-
Weinberg equilibrium. An additional 919 SNPs not present
in the HapMap CEPH (Utah residents with ancestry from
northern and western Europe) (CEU) data set were removed,
reducing the number of SNPs available for analysis to
291,531 SNPs. More than three-fourths of these SNPs
(77%; n5 225,250 SNPs) were present in90% of samples.
Checks for relatedness, Mendelian inconsistencies, and
gender based on X-chromosome heterozygosity were per-
formed using PLINK [13]. One sample was dropped due
to Mendelian inconsistencies, and one duplicate sample
Table 1
Demographic and clinical characteristics of families
Characteristics
Number of families, n 41
LOAD cases sampled (%)/unaffected sampled (%) 202 (52.4)/183 (47.5)
1 Autopsy confirmed LOAD case in family (%) 31 (75.6)
Affected individuals sampled per family (n families)
3 Affected individuals 7
4 Affected individuals 156
5 Affected individuals 8
6–9 Affected individuals 8
10 Affected individuals 3
Proportion of women, n (%) 246 (64)
Age at onset of affected individuals, y, mean (SD) 75 (9.04)
Age at last examination of unaffected individuals,
y, mean (SD)
66 (12.23)
APOE allele frequency in affected individuals, n (%)
ε2 11 (3)
ε3 284 (70)
ε4 109 (27)
Abbreviations: LOAD, late-onset Alzheimer’s disease; SD, standard de-
viation.
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STRAT [14] identified a family clustering with African
American HapMap samples (Supplementary Fig.1). NIA-
LOAD confirmed the family’s African American ancestry
through recontact with the ascertainment site. This family
was removed from the analyses resulting in 41 families
included in the linkage analyses reported here.
2.3. Statistical analyses
Autosomal andX-chromosome linkage analyseswere per-
formed using Merlin [15] and included parametric two-point
affected individuals–only and age-dependent penetrance
models and a nonparametric multipoint analysis. Parametric
multipoint analysis was performed on significant overlapping
regions between the families in this report and a companion
analysis in Hispanics (Barral et al. [16]). The package
MINX (Merlin in X) was used for analysis of X-chromosome
SNPs. Heterogeneity LOD (HLOD) models were applied to
the two-point analyses to allow for detection of linkage in
the presence of locus heterogeneity [17]. Whittemore and
Halpern NPL-pair and NPL-all statistics [18] and Kong and
Cox linear model logarithm of odds (LOD*) scores [19]
were calculated for the nonparametric multipoint analysis.
Power analyses using SIMLINK [20] on the 41 families in
the linkage analysis, with a dominant model and disease
allele frequency of 0.001, showed we have .80% power to
generate an LOD.3 for a fully informative (a5 1) age pene-
trance model with marker locus allele frequencies equal to
0.2 (MAXLOD5 5.62) and 0.4 (MAXLOD5 6.86). Using
these same paramaters, the affected individuals–only model
has.80%power to generate an LOD.2with amarker locus
frequency of 0.4 (MAXLOD 5 3.61) and 0.71% power to
produce an LOD .2 with a marker locus frequency of 0.2
(MAXLOD 5 3.00). Using a heterogeneity model(a 5 0.5) reduced power to generate an LOD .2 to 41%
and 18% for the age-penentrance and affected individuals–
only models, respectively (Supplementary Table 1).
Parameters for the parametric two-point models assumed
dominant inheritance, a disease allele frequency of 0.001
and penetrances of 0.01, 0.90, and 0.90 (representing NN,
NA, AA genotypes, respectively). Age-dependent pene-
trances used in the analysis are listed in Supplementary
Table 2. Two-point parametric analysis used all SNPs for
each of the analyses. The nonparametric multipoint scan
included a linkage disequilibrium (LD)–pruned set of
119,555 SNPs common to all genotype platforms. LD prun-
ing was done using the independent pairwise LD pruning op-
tion in PLINK (default settings). Mean distance between
markers for the set of nonparametric multipoint markers is
4.55 cM. As some pedigrees were too large for MERLIN
to perform nonparametric linkage analysis, uninformative
family members (based on an individual’s position in the
pedigree and/or absence of genotyping) were trimmed
before performing analyses using the program PowerTrim
[21]. Allele frequencies for all SNPs were based on CEU
HapMap data [22].
A significance threshold of HLOD 3.5 was set for the
parametric two-point linkage scans taking into account
testing of two separate parametric models. This is above the
Lander and Kruglyak [23] recommendations for significance
(LOD3.3;P value5 4.9! 1025) in LOD score analyses of
densemarker genome-wide linkage scans and approximates a
level suggested by Camp and Farnham [24] for testing of two
independent two-point models. Multipoint significant and
suggestive linkage thresholds were defined by LOD 3.60,
P5 2.2! 1025 and LOD 2.20, P 5 7.4! 1024, respec-
tively [23]. Linkage regions were considered independent if
the locations of their peak HLOD or LOD* scores were sepa-
rated by.20 cM.Linkage peakswere considered concordant
with previous linkage peaks or linkage peaks reported in the
companion Hispanic linkage analysis (Barral et al. [16]), if
they were 10 cM apart.
Follow-up analyses of significant multipoint results
included haplotype segregation analysis and examination
of overlapping identity-by-descent (IBD) sharing segments
for families with a maximized within family LOD 0.59,
corresponding to a nominal P value of 0.05, and 100%
IBD sharing among all affected individuals in the family.
IBD segments were determined by estimating haplotypes
in MERLIN followed by identification of IBD sharing re-
gions using Olorin [25].3. Results
3.1. Data set characteristics
The selected families have an average of eight affected
individuals (range: 4–14), with an average of five genotyped
affected individuals per family (range: 3–11; Table 1). Mean
AAO in affected individuals was 75 6 9.04, compared to a
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66 6 12.29. APOE ε2, ε3, and ε4 frequency in affected in-
dividuals (genotyped and ungenotyped) was 3%, 70%, and
27%, respectively. This compares to an ε4 frequency of
38% in NHW LOAD individuals and 14% for controls
[26], confirming the selection of LOAD families with
reduced representation of the APOE ε4 allele. APOE
genotype frequencies for affected individuals were ε2/
ε2 5 0.5%, ε2/ε3 5 4.1%, ε2/ε4 5 0.9%, ε3/ε3 5 43.2%,
ε3/ε4 5 48.6%, and ε4/ε4 5 2.7%.
3.2. Linkage results
Two-point parametric linkage analysis identified 24 SNPs
across 14 autosomal regions surpassing a significance level
of HLOD 3.5 (P value 5 3 ! 1025) (Table 2, Figs. 1
and 2). Nine of the 14 regions generated HLOD scores
that exceeded 4.0, including 3q25.31 (HLOD 5 4.15),
3q27.3 (HLOD 5 4.58), 4p34.3 (HLOD 5 4.46), 5q32
(HLOD 5 4.10), 7p21.2 (HLOD 5 4.19), 9p22.1
(HLOD 5 4.21), 11q13.4 (HLOD 5 4.74), 16q12.1
(HLOD 5 4.05), and 19q13.41 (HLOD 5 4.76). As
expected based on the family selection criteria for
exclusion of clustering of affected subjects who were
predominantly APOE ε4, we did not observe linkage to the
APOE locus. Age-dependent penetrance HLOD scoresTable 2
Two-point parametric linkage analysis results with HLODs 3.5
Chr BP (Hg19)
Cytogenic
location RS ID
Ref
allele
Alt
allele
Marker
MAF
Affected
only mod
LOD H
1 212028969 1q32.3 rs28451400 C T 0.07 3.52 3
3a 156034741 3q25.31 rs498033 G T 0.50 3.70 4
3b 186464055 3q27.3 rs6807774 A G 0.46 4.54 4
187667808 3q27.3 rs2590453 A G 0.36 3.71 3
4 174854581 4q34.1 rs7670348 C T 0.18 4.46 4
179530781 4q34.3 rs1434035 C T 0.24 4.01 4
185382061 4q35.1 rs793798 G A 0.34 4.11 4
5a 41264243 5p13.1 rs391781 A G 0.42 3.97 3
5b 145636671 5q32 rs11953090 G T 0.28 2.43 4
7 16025340 7p21.2 rs13234986 A G 0.32 4.19 4
8 101862078 8q22.3 rs4734484 C T 0.29 3.63 3
9 19051208 9p22.1 rs7022613 C T 0.47 4.21 4
11 60047410 11q12.2 rs1426248 G A 0.28 4.68 4
63197930 11q12.3 rs7934347 G A 0.22 3.85 3
73317931 11q13.4 rs737586 A G 0.17 4.74 4
75012535 11q13.4 rs506233 T C 0.45 3.59 3
78879841 11q14.1 rs4359232 T C 0.42 4.26 4
83831259 11q14.1 rs7108582 A C 0.09 3.74 3
13 46047499 13q14.13 rs2985987 G A 0.14 3.56 3
14 36681923 14q13.3 rs1766132 G A 0.17 3.92 3
16 52112372 16q12.1 rs3743795 T G 0.32 3.23 4
19 52668414 19q13.41 rs919271 A G 0.18 4.76 4
52670905 19q13.41 rs7246914 C T 0.24 4.33 4
52699440 19q13.41 rs6509626 C T 0.10 3.36 4
Abbreviations: HLOD, heterogeneity LOD; BP, base pairs in GCHr17/Hg19; M
*GWAS locus based on Lambert et al. [1].
yReference for previous evidence of linkage in region based on a significant twwere generally lower than our affected individuals–only
HLOD scores. Most SNPs generated HLOD scores
with alpha values equal to 1.0, suggesting modest contribu-
tions to individual loci by each family. No significant
results were observed for the overall analyses on the
X-chromosome; however, two families had nominally sig-
nificant LOD scores of 1.39 and 1.14 at Xq28 (rs5963398),
the location of the highest HLOD score on the X-chromo-
some (HLOD 5 2.07).
Nonparametric multipoint analyses identified an addi-
tional significant region at 14q32.2 (LOD* 5 4.18; Fig. 2).
Two-point results for this region were also supportive
of linkage (HLOD 5 2.82 at rs9323997; affected in-
dividuals–only model). One other region produced sugges-
tive multipoint results, 4q34.1–4q34.3 (LOD 5 2.40)
and was supported by a significant two-point linkage
(HLOD 5 4.46; affected individuals–only model). Please
see Supplementary Table 3 for the 1-LOD region and genes
within this region. No significant multipoint results were
observed on the X-chromosome.
3.3. Localization of region at 14q32.2
The resulting 1-LOD region [17] at 14q32.2 is a
0.78-Mbp segment between map positions 98.81 Mbp and
99.59 Mbp and contains one gene (C14orf177) and oneindividuals–
el
Age penetrance
model
GWAS locus*
(closest gene)
Previous
evidence
for regionyLOD Alpha LOD HLOD Alpha
.53 1 2.03 2.03 1 1q32.2 (CR1)
.15 0.87 3.99 3.99 1 [27]
.58 0.95 2.85 2.85 1
.71 1 2.52 2.52 1
.46 1 1.66 1.66 1
.01 1 1.61 1.61 1
.11 1 2.52 2.52 1
.97 0.93 1.24 1.34 0.82
.10 0.75 0.00 0.57 0.40
.19 1 2.24 2.24 1 [28]
.63 1 0.93 1.01 0.81
.21 1 1.42 1.42 1 [29]
.68 1 2.40 2.40 1 11q12.2 (MS4A6A-
MS4A4E).88 0.94 1.44 1.51 0.88
.74 1 2.15 2.15 1
.88 0.87 1.02 1.35 0.75
.26 1 1.74 1.74 1
.74 1 1.70 1.70 1
.56 0.93 2.54 2.54 1
.92 1 2.05 2.05 1
.05 0.84 2.23 2.23 1
.76 1 3.23 3.23 1
.33 1 2.90 2.90 1 CD33 (19q13.41)
.64 0.87 1.87 1.87 1
AF, minor allele frequency; LOD, logarithm of odds.
o-point (LOD 3.3) or multipoint (LOD 3.6) score.
Fig. 1. Manhattan plot of parametric two-point affected individuals–only results (Red lines represent HLOD 5 3.5 for significant linkage and 4.0 for highly
significant linkage). Abbreviation: HLOD, heterogeneity logarithm of odds.
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of California, Santa Cruz Genes Track [30]. The pseudogene
ribosomal protein L3 psudeogene 4 (RPL3P4) also locates to
this segment according to the Gencode database (version 19)
[31]. Linked pedigree IBD sharing analyses among the four
nominally significantly linked pedigrees (LOD*0.59) iso-
lated a 0.40-Mbp segment containing one gene, BCL11B,
located just outside the 1-LOD region, and Mir_320
(Fig. 2). Haplotype segregation of these four pedigrees illus-
trated using the software program Progeny (Progeny Soft-
ware LLC, Delray Beach, FL; www.progenygenetics.com)
is shown in Supplementary Figs. 2–5. Merlin software was
used for haplotype construction and inference.4. Discussion
We report 14 significant two-point linkage regions
(HLOD 3.5), and one significant multipoint region
(LOD*  3.6) identified by analysis of 41 multiplex
LOAD families that were selected on the basis of the absence
of variants at known risk loci, apparent dominant inheritance
of disease, and little evidence for association of LOAD with
the APOE ε4 allele. Five of the 14 two-point regions are sup-
ported by multipoint results within a 1-LOD unit confidence
interval with a minimum LOD* 1.5 (3q25.31, 4q34.1,
8q22.3, 11q12.2–14.1, and 19q13.41). The finding of
numerous significantly linked loci instead of a few shared
loci suggests that there is substantial locus heterogeneity
within familial LOAD.
Three of the 14 two-point loci are novel linkage regions
for LOAD (5q32, 11q12.2–11q14.1, and 14q13.3). The 11
other loci overlap previously reported LOAD regionsincluding five significant loci (3q25.31, 7p21.2, 9p22.1,
11q12.2–11q14.1, and 19q13.41) also showing significant
linkage (two-point HLOD 3.3, multipoint LOD* 3.6)
or association (P 5! 1028) in at least one previous report
(Table 2). These include two loci reported in the largest
LOAD genome-wide association study to date, namely the
11q12.2–11q14.1 locus which overlaps the MS4A6A-
MS4A4E association region and the 19q13.41 locus which
contains CD33 [1]. One additional GWAS locus (CR1 at
1q32.2) is near a significantly linked marker at 1q32.3. A
check of our linked SNPs in these regions for association
with LOAD in the International Genomics of Alzheimer’s
Project GWAS summary statistics found no significant asso-
ciations after correction for multiple testing (P 5! 1028;
Supplementary Table 4) [1]. The 7p21.2 and 9p22.1 loci
replicate significant linkage from reports that contain fam-
ilies used in the present analyses (Table 2). The number of
pedigree members and the phenotypes and genotypes from
the previous reports have been continuously expanded and
updated since their previous linkage reports, however, and
these updates are most likely increasing power to localize
linkage in this current report.
The locus at 14q32.2 is arguably our most robust result
given its significant multipoint LOD* score supported by
suggestive two-point scores. This locus is a considerable dis-
tance (w33 cM) from the PSEN1 locus at 14q24. Suggestive
linkage (two-point LOD5 2.60) has been reported at 14q32
in an AAO linkage analysis in Hispanic LOAD families [32].
The 1-LOD limit identified a region 0.78 Mbp in length con-
taining C14orf177 and Mir_320, both of which have some
support for involvement in dementia-related disease and
processes. C14orf177 for instance, has been associated
Fig. 2. Shared IBD segments among the four families with LOD*.0.588 and full IBD sharing for all affected, genotyped family members in the chromosome
14 linkage region. Red lines represent the minimum shared IBD segment region. Light green lines represent the 1-LOD confidence interval region. Abbrevi-
ations: IBD, identity by descent; LOD*, logarithm of odds; LOAD, late-onset Alzheimer’s disease.
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tein cholesterol levels [34], whereas members of the mir-320
miRNA family are significantly altered in sporadic AD
brains [35] and associated with both neurite outgrowth
[36] and neurodegeneration [37]. Evidence for genomic
features with regulatory potential such as several expressed
sequence tags and long non-coding RNAs also exists in the
region (based on UCSC genome browser data) [30],
including one lincRNA in particular, TCONS_12_
00008237, which is highly expressed in brain [38,39].
The region narrowed by IBD analysis in the subset of ped-
igrees most likely to be linked to 14q32.2 also includes
BCL11B, which is a transcription factor and regulator
of brain-derived neurotrophic factor (BDNF) signaling [40],
a pathway associated with pathogenesis of several neurode-
generative diseases, including LOAD [41]. BCL11B is pre-
dominantly expressed in striatal neurons and may play an
important role in adult neurogenesis [42], a process that
when dysregulated may lead to AD [43]. BCL11B is thought
to primarily reduce BDNF signaling [40], consistent with
observations that BDNF serum and expression levels
are decreased in AD [41,44,45] and high BDNF levels
protect against AD [46,47]. A recent neuroimaging study
implicated a role for BDNF in cognitive decline in LOAD
patients [48], although AD genetic association studies ofBDNF yielded conflicting results [44,49]. Finally, it has
been suggested that BDNF-based drugs might be effective
therapies for AD and other neurodegenerative diseases [50],
with targeting ofBCL11B interactionswith BDNFeven being
suggested as a feasible therapeutic approach to elevate BDNF
signaling in neurodegenerative drug development [40].
The accompanying study in Caribbean Hispanics by
Barral et al. [16] found strong evidence for linkage and
association near one of our significant loci, 11q12.2–
11q14.1. As noted previously, the chromosome 11q12.2–
11q14.1 locus is also a significant LOAD GWAS locus
from Lambert et al. [1]. Parametric affected individuals–
only analysis of this region produced a multipoint peak
LOD* of 1.18. An alpha of 0.17 suggests that only a small
number of pedigrees are potentially segregating a variant
in this region. A combined association and linkage anal-
ysis of all markers in this region using CAPL [51] pro-
duced no suggestive or significantly associated SNPs
(data not shown). One possible explanation for this
finding is lack of power for combined linkage and associ-
ation analysis using these data. Several other significant
loci from the Barral et al. study had suggestive linkage
in our analyses, including 3q13.31 (HLOD 5 3.31),
3q22.3 (HLOD 5 3.18), 6q25.3 (HLOD 5 3.02), 7p14.3
(HLOD 5 3.05), and 14q12 (HLOD 5 3.31;
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ously reported as a potential locus for LOAD in a linkage
study of a family containing four relatives with LOAD but
without tau pathology (LOD 5 4.1) [52] and in a genome-
wide linkage study of Dutch families (LOD 5 4.3;
HLOD 5 4.4) [53].
In summary, we report 15 significant regions for linkage,
including novel evidence for linkage at 5q32, 11q12.2–
11q14.1, and 14q13.3. Several of our regions overlap signif-
icant loci from previous LOAD analyses, including GWAS
regions at MS4A6A-MS4A4E and CD33. Our strong multi-
point result at 14q32.2 is particularly interesting, as it local-
izes to a region with a limited amount number of genomic
candidates, most with plausible links to dementia-related
processes and disease.
The 41 families included in these analyses are undergoing
whole-genome sequencing (WGS) as part of the National
Institute of Health’s Alzheimer’s Disease Sequencing Proj-
ect (ADSP) [54]. ADSP WGS variants located in these link-
age regions will be primary candidates for examination as
contributing to risk or protection for LOAD. Analyses
planned by the ADSP to identify these variants include (1)
combined linkage and association analyses, and (2) filtering
for rare, damaging variants in shared familial segments. An
ADSP replication phase will follow to confirm and validate
candidate loci from the discovery phase.Acknowledgments
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1. Systematic review: PubMed and Google Scholar
were used to search for articles related to genetic
linkage and genetic association analyses of Alz-
heimer’s disease (AD). In addition, we searched
for literature relating our significant loci to AD
and neurodegeneration through a search of each
significant chromosomal band (and gene features
from the significant multipoint result) and the terms
“Alzheimer’s” and “Neurodegeneration.” Relevant
research relating our significant loci to Alzheimer’s
or neurodegeneration is cited.
2. Interpretation: These findings pinpoint several novel
genomic regions linked to increased risk of familial
AD, including a region on 14q32.2 containing
a gene that regulates brain-derived neurotrophic
signaling and the 11q12.2 region previously linked to
AD through large genome-wide association analyses
of late-onset Alzheimer’s disease (LOAD).
3. Future directions: Identification of these loci as
linked to familial AD provides an exciting opportu-
nity to identify causal variants for LOAD through
prioritization of these regions for analyses in forth-
coming whole-genome sequencing.References
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